Accessibility Menu
ProKidney logo

ProKidney(NASDAQ) PROK

Market Cap$296.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-85%
5 Year-85%
1 Year-38%
1 Month-11%
Premium Feature
Moneyball Superscore
48/100
$1.42
-4.05%
-0.06Today
ProKidney last closing stock price
MetricPriceDate
Last closeUSD 1.422026-08-20
ProKidney stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.07%USD 1.412026-08-13
1 month-10.97%USD 1.602026-07-21
3 month-18.86%USD 1.752026-05-22
Year to date-36.61%USD 2.242025-12-31
1 year-37.72%USD 2.282025-08-20
3 year-84.76%USD 9.322023-08-21
5 year-85.47%USD 9.772021-08-20
Since inception-85.36%USD 10.112021-06-30

ProKidney Financials at a Glance

Market Cap

$296.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$818.00K

Net Income (TTM)

-$86.71M

EPS (TTM)

-$0.55

P/E Ratio

-2.57

Dividend

$0.00

Beta (Volatility)

1.39 (Average)

Price

$1.42

Volume

3,255

Open

$1.47

Previous Close

$1.42

Daily Range

$1.38 - $1.47

52-Week Range

$1.30 - $3.48

Estimated Earnings Date

Nov 9, 2026

PROK News

Foolcom-Featured.png

ProKidney Reports 78 Percent Gain in Q2

Motley Fool Markets TeamAug 12, 2025
happy-investors-checking-holdings

Meet the Biotech Stock That Rocketed 775% Higher

Cory RenauerJul 22, 2025
Person working in a lab.

This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy?

David Jagielski, CPAJul 17, 2025
adaptimmune

Why Shares of ProKidney Were Dropping Thursday

James HalleyOct 12, 2023

PROK: Motley Fool Moneyball Superscore

48

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ProKidney

ProKidney makes treatments to help people keep their kidneys working. It uses a person's own cells to repair their damaged organs. This helps patients who have kidney disease caused by diabetes.

A New Way to Treat Kidneys

  • rilparencel: Lead cell therapy candidate currently in Phase 3 clinical trials; designed to preserve kidney function in patients with advanced chronic kidney disease and type 2 diabetes.
  • Selected Renal Cells: Autologous cells taken from a patient and prepared for reinjection; eliminates the need for the lifelong immune-suppressing drugs required for traditional transplants.
  • Leasing Services: Property management for two buildings in North Carolina; accounts for 100% of revenue as the company has no approved products.

Building a Foundation for Growth

  • Completed a domestication process to move the legal home from the Cayman Islands to Delaware on July 1, 2025.
  • Entered a sales agreement with Jefferies LLC in July 2025 to sell up to $200 million in stock over time.
  • Amended the Phase 3 study protocol for rilparencel to focus on specific stages of chronic kidney disease.
  • Expanded internal manufacturing capacity through a $3.4 million investment during the six-month period ended June 30, 2026.

The Personalized Medicine Advantage

The company uses a proprietary process to create personalized medicine from a patient's own tissue. This approach targets the underlying cause of kidney decline rather than just managing symptoms or preparing for failure.

Key Figures and Funding

  • Net loss was $46.4 million for the three months ended June 30, 2026.
  • Research and development expenses rose to $69.9 million for the six-month period ended June 30, 2026.
  • Cash, cash equivalents, and marketable securities are expected to fund operations into mid-2027.
  • Market capitalization was $568.3 million according to recent data.

The Path Ahead

ProKidney has transitioned from an early-stage researcher to a late-clinical-stage developer of personalized cell therapies. Its shift toward late-stage trials and expanded manufacturing reflects a focus on bringing laboratory science to patients with chronic disease.

AI Generated • Aug 11, 2026

Industry

Biotechnology

Sector

Health Care

Employees

231

CEO

Bruce Culleton, MD, MBA

Website

www.prokidney.com

Headquarters

Winston-Salem, NC 27103, US

PROK Financials

Key Financial Metrics (TTM)

Gross Margin

-252.57%

Operating Margin

-21664.55%

Net Income Margin

-10599.76%

Return on Equity

8.83%

Return on Capital

N/A

Return on Assets

-34.82%

Earnings Yield

-38.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$296.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

208.93M

Volume

3.25K

Avg. Volume

1.23M

Financials (TTM)

Gross Profit

-$2.07M

Operating Income

-$177.22M

EBITDA

-$160.75M

Operating Cash Flow

-$141.17M

Capital Expenditure

-$18.57M

Free Cash Flow

-$159.73M

Cash & ST Invst.

$181.56M

Total Debt

$3.52M

ProKidney Performance Analysis

ProKidney annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 76,000N/A
20252025-12-31USD 893,0001075.0%
ProKidney sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-1.8%
Q42025-12-313.7%
Q12026-03-310.4%
Q22026-06-30-33.6%
ProKidney annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.7695.9%
20232023-12-31USD -0.57-67.3%
20242024-12-31USD -0.628.7%
20252025-12-31USD -0.52-17.6%
ProKidney sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.7%
Q42025-12-31-16.7%
Q12026-03-31-14.3%
Q22026-06-306.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$150.00K

-32.1%

Gross Profit

$150.00K

-32.1%

Gross Margin

100.00%

N/A

Market Cap

$296.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.28M

N/A

Employees

231

N/A

Net Income

-$28.42M

-71.7%

EBITDA

-$44.99M

-29.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$181.56M

-38.4%

Total Debt

$3.52M

-20.3%

Accounts Receivable

$956.00K

-46.1%

Inventory

$0.00

N/A

Long Term Debt

$2.39M

-31.9%

Short Term Debt

$1.13M

+25.0%

Return on Assets

-34.82%

N/A

Return on Invested Capital

-78.31%

N/A

Free Cash Flow

-$44.21M

-28.0%

Operating Cash Flow

-$40.37M

-28.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RZLTRezolute, Inc.
$4.66-1.27%
EYPTEyePoint Pharmaceuticals, Inc.
$5.40-14.29%
PRMEPrime Medicine, Inc.
$3.24-8.47%
KURAKura Oncology, Inc.
$11.71-6.54%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$41.20+0.06%
MSTRStrategy
$112.39+0.08%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$17.55+0.11%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$122.21+0.01%

Questions About PROK

What is the current price of ProKidney?

ProKidney is trading at $1.42 per share.

What is the 52-week range for ProKidney?

Over the past 52 weeks, ProKidney has traded between $1.30 and $3.48.

How much debt does ProKidney have?

As of the most recent reporting period, ProKidney reported total debt of $3.52M.

How much cash does ProKidney have on hand?

ProKidney reported $74.87M in cash and cash equivalents in its most recent financial results.

What is ProKidney’s dividend yield?

ProKidney does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services